Status:
COMPLETED
A Double-Blind, Placebo-Controlled Trial of Anti-Aging, Pro-Autophagy Effects of Metformin in Adults With Prediabetes
Lead Sponsor:
University of New Mexico
Conditions:
PreDiabetes
Aging
Eligibility:
All Genders
30-70 years
Phase:
PHASE3
Brief Summary
The goal of this pilot and feasibility study is to investigate the effects of a short course of metformin therapy on a surrogate marker of cellular senescence and autophagy among adult patients with p...
Detailed Description
Anti-aging medicine is a burgeoning field. Accumulating evidence implicates the cellular process of autophagy as a primary mechanism of normal aging and the diseases associated with it. Autophagy is a...
Eligibility Criteria
Inclusion
- Adults with prediabetes (defined as an A1c of 5.7-6.4%)
- BMI between 27 and 40 kg/m2 (inclusive).
Exclusion
- Prior treatment with metformin or other diabetes medications,
- Pregnancy,
- Significant renal dysfunction (Serum Creatinine \> 1.3 mg/dl for women, \> 1.4 mg/dl for men),
- Severe hepatic dysfunction (aspartate amnotransferease \[AST\] or alanine aminotransferase \[ALT\] \> 3 times the upper limit of normal),
- Ongoing alcohol or substance abuse,
- Inflammatory bowel disease,
- Ongoing glucocorticoid therapy,
- Or inability to render informed consent.
Key Trial Info
Start Date :
September 1 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 20 2020
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT03309007
Start Date
September 1 2017
End Date
August 20 2020
Last Update
December 11 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of New Mexico Clincal & Translational Science Center
Albuquerque, New Mexico, United States, 87131